Japan gears up for year of reform
This article was originally published in Clinica
Japanese medical device regulators and advisors at home and overseas are preparing for a year of medical device regulatory reform and continuing dialogue on reimbursement and pricing under Prime Minister Koizumi's liberalisation drive. As of this month, it is expected that the device-related aspects of the Pharmaceutical Affairs Law (PAL) reform will begin to be filled out with up to 100 guidance documents, with European and US regulators and industry playing a role in the consultation.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.